to-watch

to-watch

The Big4Bio Company to Watch Program
June 2023: Startup Stadium Finalists at BIO 2023

/

Start-Up Stadium is designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, strategic partners, and non-dilutive capital at the world’s largest biotechnology partnering event. During the 2023 BIO International Convention select finalists from around the world will share a quick pitch showcasing new technologies and therapeutic solutions […]

Read More

Podcast: Pioneering Fully Programmable Medicines

/

In the third of four features on Senda Biosciences, we spoke to Senda CEO Guillaume Pfefer and Senda Chief Platform Officer Stuart Milstein, about its platform technology, how it is building an atlas of natural nanoparticles, and how its work is leading to a pipeline of programmable medicines. Companies to Watch – Senda Biosciences The Big4Bio […]

Read More

Medicines with Unlimited Possibility

/

The second of four features on Senda Biosciences, based on Big4Bio’s interview with CEO Guillaume Pfefer and Chief Platform Officer Stuart Milstein, focuses on the company’s technology platform – designed to harness nature’s codes to program molecules within and to the cell – and its potential to treat a broad range of diseases. Companies to […]

Read More

The Big4Bio Company to Watch Program
April 2023: Senda Biosciences

/

  THE COMPANY/THE MISSION Programming Medicine to Send the Right Information to the Right Cell Senda Biosciences is on a mission to harness powerful molecular interactions that have evolved over millennia between humans, plants, and bacteria to develop new types of medicines.   THE TECHNOLOGY, PART 1 Medicines with Unlimited Possibility Discussing the company’s technology […]

Read More

Programming Medicine to Send the Right Information to the Right Cell

/

In the first of four features on Senda Biosciences, Big4Bio spoke with CEO Guillaume Pfefer and Chief Platform Officer Stuart Milstein about how and why the company was founded, and how molecular connections among different kingdoms of life that have co-evolved over millennia may hold the key to addressing the challenges of delivering nucleic acid […]

Read More

The Big4Bio Company to Watch Program
September 2022: Life Science Cares

/

Life Science Cares leverages the power of the life science industry to solve one of our most intractable social issues—poverty. They currently operate in locations that boast a critical mass of companies working in biotech, pharmaceuticals, medical technology, and research: Boston, Philadelphia, San Diego and the San Francisco Bay Area — the Big4Bio regions. Life […]

Read More

The Big4Bio Company to Watch Program
June 2022: WIB-FAST Advisory Program Startups

/

The WIB-FAST Advisory Program launched in May with the following five women-led startups who are developing innovative and transformational therapeutic, diagnostic or device technologies to improve human health: Curiva MyoGene Bio NeurANO Bioscience SiVEC Biotechnologies TNC Medical WIB-FAST at BIO2022 In the weeks leading up to the BIO International Convention, the founders will receive customized commercialization […]

Read More

Advancing a New Class of Medicines

/

Company to Watch – NeuBase Therapeutics In the second of four features on NeuBase Therapeutics, Big4Bio spoke with Founder and CEO Dietrich Stephan and CFO Todd Branning about the company’s precision genetic medicine technology and pipeline, partnering and financing activities, and plans moving forward. By Marie Daghlian Todd Branning, chief financial officer of NeuBase Therapeutics, […]

Read More

The Big4Bio Company to Watch Program
April 2022: Neubase

/

  THE COMPANY Drugging the Genome The spark behind NeuBase’s founding, and how the company is drugging the genome with precision genetic medicine.     THE TECHNOLOGY Advancing a New Class of Medicines Founder and CEO Dietrich Stephan and CFO Todd Branning talk about the company’s precision genetic medicine technology and pipeline.       […]

Read More

Drugging the Genome

/

Company to Watch – NeuBase Therapeutics In the first of four features on NeuBase Therapeutics, Big4Bio spoke with Founder and CEO Dietrich Stephan and CFO Todd Branning about the spark behind founding of the company, and how it is drugging the genome with precision genetic medicine. The second feature will provide an in-depth focus on […]

Read More

Modelling Biology: A Q&A with Cellarity’s CSO

/

Company to Watch – Cellarity In the final article in the Company to Watch series on Cellarity, Big4Bio editor Marie Daghlian spoke with Chief Scientific Officer Laurens Kruidenier about what impressed him about the company, what he sees as the strength of the Cellarity platform and how it works, and why we should keep our […]

Read More

Podcast: Transforming Drug Discovery by Focusing on Cell Behavior

/

Companies to Watch – Cellarity The Big4Bio Podcast · Transforming Drug Discovery by Focusing on Cell Behavior   Fabrice Chouraqui, CEO of Cellarity, speaks about the company’s approach to drug discovery, the technology it is harnessing, and why focusing on cells rather than molecular targets are a better way to discover drugs.     This […]

Read More

A Platform to Uncover Biological Complexity to Target Virtually Any Disease

/

Company to Watch – Cellarity In the second of four features on Cellarity, Big4Bio spoke with CEO Fabrice Chouraqui about the company’s unique platform, initial pipeline, and plans moving forward. by Marie Daghlian Cellarity aims to discover medicines that can resolve human disease, potentially any disease. To do this it has developed a cell-centric platform […]

Read More